LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway

Internal tandem duplications (ITD) mutation within FMS-like tyrosine kinase 3 (FLT3), the most frequent mutation happens in almost 20% acute myeloid leukemia (AML) patients, always predicts a poor prognosis. As a small molecule tyrosine kinase inhibitor, sorafenib is clinically used for the treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Amin, Zeng, Peiting, Li, Yinguang, Lu, Wenhua, Lai, Yaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606661/
https://www.ncbi.nlm.nih.gov/pubmed/34820336
http://dx.doi.org/10.3389/fonc.2021.782065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606661/
https://www.ncbi.nlm.nih.gov/pubmed/34820336
http://dx.doi.org/10.3389/fonc.2021.782065

Ejemplares similares